The Value of Pandemic Preparedness

Rachel Glennerster (University of Chicago) November 22, 2022

Joint work with:
Christopher Snyder (Dartmouth College)
Brandon Tan (IMF)



Outline

- Estimate
 - the frequency and costs of previous pandemics
 - expected losses from future pandemics (\$800bn a year, \$130bn for EU)
 - value of investments that reduce severity of next pandemic
- Different ways to incentivize innovation to prevent pandemics



Estimating frequency and severity of pandemics (Marani et al 2021)

Challenge in estimating frequency and severity of future pandemics:

- Need long time horizon as infrequent
- But frequencies change (eg antibiotics)

Marani et al use data from 1600 and find a stable relationship between smaller and larger epidemics

Then use data from last 20 years to estimate current frequency and severity

We build on this approach.







Figure 1. Relationship Between Epidemic Intensity Economic Losses in Historical Pandemics.



Notes: Data points from Table 1. Regression line given by equation (6). Log scales used for both axes.



	Economic output	Y	
The state of the s	Leonomic output	Learning	Total
$V(\overline{ML})$	$AV(\overline{OL})$	$AV(\overline{LL})$	$AV(\overline{TL})$
05	176	127	808
52	88	64	404
	100	120	044
			944 2144
327	450	326	2103
			646 990
3	05 52 33 312 327	176 176 180 1812 193 140 176	05 176 127 52 88 64 33 180 130 312 193 140 327 450 326 34 176 127



Value to accelerated response to pandemics

Covid-19

- IMF estimated \$1-\$1.4 trillion loss of GDP per month,
- Jan 2021, capacity to produce one vaccine a year worth \$5,800 (Castillo et al 2021), price \$6-\$40
- \$13bn Operation Warp Speed paid for itself if accelerated widespread US vaccination by 12 hours
- But took 2 years from vaccine approval to enough supply to vaccinate 70% world population

Implication

- Investment now that would speed up widespread protection against worst effects of future pandemic would generate high returns
- Social pressure to keep prices down in pandemic reduces private sector investment, requires government support



	Costs and benefits of program to undertake vaccination campaign in next significant pandemic (billion \$)			
	With advance investment	Without advance investment	Difference	
Current value of expenditures				
 Initial advance investment 	60	0	60	
 Annual maintenance of advance capacity 	5	0	5	
Additional expenditures in pandemic	22	53	-32	
Present value of program outcomes				
 Expected program costs (net of rental income) 	48	21	27	
 Expected gross benefits 	636	199	437	
 Expected net benefits 	587	178	409	

For EU cost and benefits, multiply by 0.16.



Ways to incentivize broad spectrum antivirals

- Fund particular research teams (push)
 - Assumes you know who is most likely to succeed
 - Does not incentivize large production
 - Good for early-stage research (if given to multiple groups), not for production
- Advance market commitment
 - Commit to buy a large (prespecified) quantity at prespecified price if meets technical requirements
 - Open to whoever develops the best product fastest
 - Incentivizes large scale production (market incentives are to produce small quantities)

